2026 Nobel Prize in Medicine goes to optogenetics, the technology that turns neurons on with light.

The 2026 Nobel Prize in Medicine has been awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for discoveries on light-activated ion channels and optogenetics. The announcement was made today at 11:30 a.m. The American Deisseroth (Stanford University) and the Germans Hegemann (Humboldt University of Berlin) and Nagel (University of Würzburg) developed a technology that allows specific nerve cells to be activated or deactivated using light pulses.

This technique, described as "one of the most spectacular revolutions in contemporary neuroscience," enables the precise control of individual neuron activity with extraordinary accuracy. According to experts, optogenetics paves the way for significant discoveries against neurological diseases such as Alzheimer's, Parkinson's, depression, and anxiety, in addition to potential applications for treating some forms of congenital blindness.

Optogenetics originated from the study of a green algae called Chlamydomonas. Researchers discovered that this algae contains light-sensitive proteins called channelrhodopsins, which function as biological switches activated by light. The decisive breakthrough occurred when Karl Deisseroth introduced the gene for these proteins into neurons, demonstrating in 2005 that illuminating them with blue light could trigger a nerve signal.

Two years later, the principle was successfully applied to nerve cells in the brains of living mice, giving rise to a true "biological switch" controlled by light. For the first time, it became possible not only to observe which neurons activate during specific brain functions but also to turn them on or off voluntarily to study their causal role. This technology quickly spread to thousands of laboratories worldwide, radically transforming the study of the brain and neurological diseases.